International society for pharmacoeconomics and outcomes research comments on the American society of clinical oncology value framework

Journal of Clinical Oncology

Volumn 34, Issue 24, 2016, Pages 2936-2937

  Malone, Daniel C ^a   Berg, Nancy S ^b   Claxton, Karl ^c   Garrison, Louis P ^d   Ijzerman, Maarten ^e   Marsh, Kevin ^f   Neumann, Peter J ^g   Sculpher, Mark ^c   Towse, Adrian ^h   Uyl De Groot, Carin ⁱ   Weinstein, Milton C ^j  

^a UNIVERSITY OF ARIZONA   (United States)

^b International Society for Pharmacoeconomics and Outcomes Research   (United States)

^c UNIVERSITY OF YORK   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF TWENTE   (Netherlands)

^f EVIDERA   (United Kingdom)

^g TUFTS MEDICAL CENTER   (United States)

^h Office of Health Economics   (United Kingdom)

ⁱ ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CANCER THERAPY; CLINICAL DECISION MAKING; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; LETTER; ONCOLOGIST; OUTCOMES RESEARCH; PATIENT DECISION MAKING; PATIENT PREFERENCE; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; OUTCOME ASSESSMENT;

ECONOMICS, PHARMACEUTICAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84982151756     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.4328     Document Type: Letter

References (5)

1. Schnipper LE, Davidson NE, Wollins DS, et al: American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33:2563-2577, 2015
2. Cherny NI, Sullivan R, Dafni U, et al: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 26:1547-1573, 2015
3. Anderson JL, Heidenreich PA, Barnett PG, et al: ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63:2304-2322, 2014
4. Tufts Medical Center, Center for the Evaluation of Value and Risk in Health: Cost-Effectiveness Analysis Registry. www.cearegistry.org
5. Schnipper LE, Davidson NE, Wollins DS, et al: Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received. J Clin Oncol 34:2925-2934, 2016